CASE REPORT

Renal Mucinous Tubular and Spindle Cell Carcinoma Shows a High Uptake on $^{18}$F-FDG PET/CT

Sho Furuya¹, Osamu Manabe², Toshikazu Nanbu¹, Noboru Yamashita³, Yuuichirou Shinnno³, Kiyoshi Kasai¹, Markus Kroenke²,³ and Nagara Tamaki²

Abstract:
We herein report a rare case of mucinous tubular and spindle cell carcinoma (MTSCC) in an 80-year-old woman. A well circumscribed tumor located on the right kidney was discovered incidentally as a result of screening non-contrast CT. FDG PET/CT showed the increased tracer accumulation in the tumor. The histological diagnosis was MTSCC, which is a rare and only recently established subtype of the malignant renal cell carcinoma (RCC). The present case suggests the clinical benefit of a high uptake of FDG combined with enhanced contrast CT in the differentiation of MTSCCs and other RCCs.

Key words: mucinous tubular and spindle cell carcinoma, renal cell carcinoma, FDG PET/CT

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.9523-17)

Case Presentation

We herein report a rare case of mucinous tubular and spindle cell carcinoma (MTCC) in an 80-year-old woman. The patient, who was a nonsmoker had a medical history of hypertension and was using antihypertensive drugs. A well circumscribed tumor located on the right kidney was discovered incidentally as a result of a non-contrast screening CT (Fig. 1A). Contrast-enhanced CT revealed a spherical mass with an inhomogeneous and comparatively slow wash-in contrast enhancement pattern (Fig. 1D and E). $^{18}$F-FDG PET/CT showed the increased accumulation of tracer in the tumor, with an SUVmax of 28.6 (Fig. 1B and C). The results of biochemical analyses were as follows: fasting glucose, 104 mg/dl; creatinine, 0.71 mg/dl; urea, 12 mg/dl (the aspartate aminotransferase, alkaline phosphatase, and gamma glutamyl transferase levels were within normal ranges); white blood cells (WBCs) count, 7.4 10³/μL; hemoglobin, 12.4 g/dL; sodium, 139 mmol/L; potassium, 4.5 mmol/L; chloride, 108 mEq/L; and calcium, 9.4 mg/dL. Results of a routine urinalysis were as follows: color, clear yellow; clear ketones, negative; blood, negative; specific gravity, 1.007; bilirubin, negative; nitrites, negative; pH, 5.5; urobilirubin, 0.1 mg/dL; red blood cells, <1 /hpf; WBCs, 1-4 /hpf; epithelial cells, 1-4 /hpf; crystals, negative; bacteria, negative; and yeast, negative.

The histological diagnosis was MTSCC which is a rare and only recently established subtype of the malignant renal cell carcinoma (RCC) subtype (Fig. 2).

Discussion

MTSCC is a malignant renal cell carcinoma (RCC) subtype that has been classified as a distinct entity in the World Health Organization (WHO) classification of adult renal epithelial neoplasms since 2004. MTSCC accounts for <1% of all renal neoplasms and shows a female predominance (1). It is characterized by low-grade cuboidal cells arranged in tubules, a variable amount of bland spindle cells, and it is set within a myxoid matrix of extracellular mucin (2). Our case is highly consistent with these typical pathological findings. MTSCCs usually grow silently, are discovered incidentally, and have a favorable prognosis. Thus, MTSCCs must be differentiated from other RCCs that have a much poorer prognosis (3). Some of the CT features of MTSCCs and papil-
RCCs overlap, and differentiation between the two entities is often difficult (2). Common types of RCC (i.e., clear cell and papillary RCCs) often show only a slightly increased uptake of \(^{18}\text{F-FDG}\) (4). \(^{18}\text{F-FDG}\) is a glucose analog that enters cells through the membrane glucose transporter (GLUT) that is commonly overexpressed in malignant tumor cells. In RCC, the decreased activity of glucose-6 phosphatase (glucose-6-Pase) may be related to the accumulation of 18F-FDG, which is considered negligible in most tumors with the exception of hepatocellular carcinoma (Fig. 3). Thus, the uptake of \(^{18}\text{F-FDG}\) in RCC is limited and difficult to assess in addition to the normal renal visualization from the physiological excretion of \(^{18}\text{F-FDG}\). Reports on the utility of \(^{18}\text{F-FDG PET/CT in the diagnosis of MTSCC are limited. Ozturk reported a case of MTSCC that was diagnosed with the help of magnetic resonance imaging (MRI) and the \(^{18}\text{F-FDG PET findings (5). In this report, the obvious uptake of \(^{18}\text{F-FDG was seen in the entire mass of MTSCC. The

Figure 1. The \(^{18}\text{F-FDG PET/CT findings. A well circumscribed tumor of the right kidney was discovered incidentally as a result of a non-contrast screening CT (A). Contrast-enhanced CT revealed a 7.5×6.9 cm spherical mass with an inhomogeneous and comparatively slow wash-in contrast enhancement pattern (D, E). On \(^{18}\text{F-FDG PET/CT, the showed the increased accumulation of tracer with an SUVmax value of 28.6 (B, C).}

Figure 2. The pathological findings. Laparoscopic unilateral nephrectomy was performed and the histological diagnosis was a mucinous tubular and spindle cell carcinoma (MTSCC) based on identification of cuboidal cells arranged in tubules (A), abrupt transitions to spindle cell morphology and alciain blue staining, which revealed mucin (B).
The authors state that they have no Conflict of Interest (COI).

Mechanism of $^{18}$F-FDG accumulation in MTSCC remains unknown, the glucose metabolism pathway, including components such as GLUT and hexokinase, might be different from RCC.

Malignant lymphoma (ML) and genitourinary system tumors can be considered as differential diagnoses with a high uptake of $^{18}$F-FDG (4-6). The enhancement pattern of the mass can help to differentiate ML from most tumors. Homogenous enhancement without vascular invasion is typical for ML, which is not seen in other renal tumors (7-9). Genitourinary system tumors, such as advanced upper tract urothelial carcinoma (UTUC) extend and infiltrate into the renal parenchyma and a sessile filling defect is generally visible (10, 11). UTUC usually shows early enhancement and de-enhancement after the administration of the contrast agent. Additionally, hydronephrosis and a thickened ureteric wall with enhancement are characteristic findings that allows for differentiation from MTSCC (10, 11).

The present case suggests the clinical benefit of a high uptake of $^{18}$F-FDG combined with enhanced contrast CT in the differentiation of MTSCCs and other RCCs.

The authors state that they have no Conflict of Interest (COI).

References

1. Zhao M, He XL, Teng XD. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagn Pathol 10: 168, 2015.
2. Lopez-Beltran A, Scarpelli M, Montironi R, et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol 49: 798-805, 2006.
3. Kenney PA, Vikram R, Prasad SR, et al. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int 116: 85-92, 2015.
4. Takahashi M, Kume H, Koyama K, et al. Preoperative evaluation of renal cell carcinoma by using $^{18}$F-FDG PET/CT. Clin Nucl Med 40: 936-940, 2015.
5. Ozturk H. Renal mucinous tubular and spindle cell carcinoma and $^{18}$F-fluorodeoxyglucose-PET/CT findings. Clin Genitourin Cancer 12: e161-e166, 2014.
6. Chen C, Liu Q, Hao Q, et al. Study of 320-slice Dynamic Volume CT perfusion in Different Pathologic Types of Kidney Tumor: Preliminary Results. PLoS One 9: e85522, 2014.
7. Urban BA, Fishman EK. Fishman. Renal Lymphoma: CT Patterns with Emphasis on Helical CT. Radiographics 20: 197-212, 2000.
8. Zagoria RJ, Bechtold RE, Dyer RB. Staging of renal adenocarcinoma: role of various imaging procedures. AJR Am J Roentgenol 164: 363-370, 1995.
9. Johnson CD, Dunnick NR, Cohan RH, et al. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 148: 59-63, 1987.
10. Browne RF, Meehan CP, Colville J, et al. Transitional cell carcinoma of the upper urinary tract: spectrum of imaging findings. Radiographics 25: 1609-1627, 2005.
11. Jinzaki M, Kikuchi E, Akita H, et al. Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma. Int J Urol 23: 284-298, 2016.
